eTheRNA is a clinical-stage mRNA companies in the European healthcare sector. The company has mRNA technology discovery and development capabilities with a full platform of integrated capabilities, including own manufacturing.
As the company’s current investors were already mostly the European Tier-I healthcare investors,  the company wanted to attract new investors for their € 39M Series B, and at the same gain access to the Asian market.

What we did and delivered

• Given the company’s global cutting-edge technology and great opportunities globally, eTheRNA had a competitive advantage in China.  Partnering with Chinese pharma companies was the best way forward to gain access to the Chinese market 
• We successfully brought in a Chinese strategic lead investor & two follow investors for the €39M Series B
• We brokered the Licensing & Joint Venture deal with Grand Pharma (0512.HK)

Outcomes

• eTheRNA completed its Series B and later on its Series C
• Via its Joint Venture in China the company has now manufacturing and product development capabilities, important to launch its products locally